Radiopharm (ASX: RAD) to open RAD 204 Phase 1 lung cancer trial in January

December 27, 2023 12:40 PM AEDT | By Sonal Goyal
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp


  • Site initiation visit has been completed for RAD 204 therapeutic Phase 1 trial at Princess Alexandra Hospital in Brisbane.
  • The trial is planned to open on 4 January 2024, and the first patient is expected to be dosed in January 2024.
  • Patient pre-screening has started, marking a key milestone for the trial.

Radiopharm Theranostics Limited (ASX: RAD) has completed the site initiation visit (SIV) for the RAD 204 therapeutic Phase 1 study.

The title of the study is-

Data source: Company update

The study is the First-In-Human dose escalation trial of 177Lu-RAD 204, aimed at evaluating the safety and efficacy of 177Lu-RAD 204 in patients with advanced Non-Small Cell Lung Cancer (NSCLC). NSCLC is one of the most frequently occurring forms of lung cancer.

As per the American Cancer Society, by the end of 2023, around 300,000 new lung cancer cases will be identified in the US, of which 81% are expected to be NSCLC patients.

The trial, to be conducted at Princess Alexandra Hospital in Brisbane, Australia, will be supported by GenesisCare, an oncology care provider.


The study will be performed in 21 patients with PD-L1-positive NSCLC. The company informed that Phase 1 imaging study in 16 patients has been completed, confirming safety and biodistribution.  

The technology supporting the study is RAD’s proprietary nanobody from its NanoMabs platform. The technology targets programmed death-ligand 1 (PD-L1) – positive expression in NSCLC.

Presently, pre-screening of eligible NSCLC patients is underway, marking a significant milestone for the trial preparation. This development confirms the commitment and readiness to dose patients with 177Lu-RAD 204.

The study will be formally activated on 4 January 2024, and the first patient is expected to be dosed in January 2024.

RAD shares closed at AU$0.073 apiece on 27 December 2023.


The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

Two ASX Listed Stocks Giving Bullish Indications

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.